Epidemiology of acute and chronic hepatitis B virus infection in Norway, 1992-2009 by Rimšelienė, Gražina et al.
RESEARCH ARTICLE Open Access
Epidemiology of acute and chronic hepatitis
B virus infection in Norway, 1992-2009
Gražina Rimšelienė
1,2*, Øivind Nilsen
2, Hilde Kløvstad
2, Hans Blystad
2 and Preben Aavitsland
2
Abstract
Background: Norway is classified as a low prevalence country for hepatitis B virus infection. Vaccination is only
recommended for risk groups (intravenous drug users (IDUs), Men who have Sex with Men (MSM), immigrants and
contacts of known carriers). We describe the epidemiology of reported cases of hepatitis B in Norway, during the
years 1992-2009 in order to assess the validity of current risk groups and recommend preventive measures.
Methods: We used case based data from the national surveillance system on acute and chronic hepatitis B. The
Norwegian Statistics Bureau provided population and migration data and the Norwegian Institute for Alcohol and
Drug Research the estimated number of active IDUs between 2002-2007. Incidence rates (IR) and incidence rate
ratios (IRR) for acute hepatitis B and notification rates (NR) and notification rate ratios (NRR) for chronic hepatitis B
with 95% confidence intervals were calculated.
Results: The annual IR of acute hepatitis B ranged from 0.7/100,000 (1992) to 10.6/100,000 (1999). Transmission
occurred mainly among IDUs (64%) or through sexual contact (24%). The risk of acquiring acute hepatitis B was
highest in people aged 20-29 (IRR = 6.6 [3.3-13.3]), and in males (IRR = 2.4 [1.7-3.3]). We observed two peaks of
newly reported chronic hepatitis B cases in 2003 and 2009 (NR = 17.6/100,000 and 17.4/100,000, respectively).
Chronic hepatitis B was more likely to be diagnosed among immigrants than among Norwegians (NRR = 93 [71.9-
120.6]), and among those 20-29 compared to those 50-59 (NRR = 5.2 [3.5-7.9]).
Conclusions: IDUs remain the largest risk group for acute hepatitis B. The observed peaks of chronic hepatitis B
are related to increased immigration from high endemic countries and screening and vaccination of these groups
is important to prevent further spread of infection. Universal screening of pregnant women should be introduced.
A universal vaccination strategy should be considered, given the high cost of reaching the target populations. We
recommend evaluating the surveillance system for hepatitis B as well as the effectiveness of screening and
vaccinating immigrant populations.
Background
Two billion people have been exposed to the hepatitis B
virus (HBV), 5 million cases of acute hepatitis B occur
annually and over 350 million people have a chronic
infection [1]. In total, hepatitis B results in 500,000-1.2
million deaths annually [1]. This carcinogenic virus
causes 60-80% of the world’s hepatocellular carcinoma.
The risk is 25-35 times higher among those with
chronic HBV infection [2] causing 300,000-500,000
deaths each year [1]. Ninety percent of infants infected
during the first year of life and 30-50% of children
infected between the ages of 1 and 4 develop chronic
hepatitis B [3].
The annual incidence of reported hepatitis B in Eur-
ope varies from < 1 to 15/100,000 with the majority of
the countries reporting < 5/100,000. Case definitions
and classifications can play a role in this, as well as
inclusion criteria of chronic cases into the data [4]. The
prevalence of positive HBsAg tests in the general popu-
lation of Europe varies by country from 0.1% to 7% [5].
Norway is generally a low prevalence country (0.5%)
[6]. Certain recognised risk groups show a notably low
prevalence, such as patients undergoing dialysis (< 1%)
[7]. Low prevalence was also observed in pregnant
women (0.1%) [8]. Due to the low prevalence, only a
selective vaccination strategy is in place [9]. The
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an effect on imported chronic hepatitis B cases, which
have been perceived to represent the main disease bur-
den. Vaccine is offered to well defined risk groups, such
as injecting drug users (IDUs), contacts of known car-
riers, men who have sex with men (MSM), immigrants
from countries with a high prevalence, medical workers
and students, and newborns born to mothers from
endemic countries with medium or high prevalence.
Despite the low reported incidence of hepatitis B in
Norway, factors such as increasing intravenous drug use,
as well as increased immigration and integration of
immigrant communities are increasing the number of
individuals at risk. We aimed to describe the epidemiol-
ogy of reported cases of acute and chronic hepatitis B
virus infection in Norway between 1992 and 2009 in
order to assess the validity of current risk groups and
recommend preventive measures.
Methods
We described all cases reported to the Norwegian sur-
veillance system for communicable diseases (MSIS) with
a diagnosis of acute or chronic HBV infection between
1992 and 2009 by year of diagnosis and by sex, age, geo-
graphical location of infection, residence status, and
county/municipality. Incidence rates (IR) and incidence
rate ratios (IRR) with 95% confidence intervals (CI) for
acute hepatitis B, as well as notification rates (NR) and
notification rate ratios (NRR) of newly diagnosed cases
of chronic infection were calculated using Excel,
STATA v10.0 (STATA Corporation, College Station,
TX, USA) and Episheet software.
Existing surveillance system in Norway
Hepatitis B surveillance consists of two components:
acute and chronic HBV infection. Acute hepatitis B has
been a notifiable disease since 1975. In 1992, chronic
HBV was also made notifiable. The reporting is based
on mandatory notifications of laboratory confirmed
cases from both clinicians and laboratories to the Nor-
wegian Institute of Public Health (NIPH). The clinicians
report the route of transmi s s i o n ,i fk n o w n .A tt h e
NIPH, reports on the same patients are merged, data is
validated and following the established case definition
allocated, respectively to either the acute or chronic
HBV databases. The case definition was modified in
2007 when HBV-RNA test result was added. The
reporting and database is based on name and a unique
personal identification number, so each report is vali-
dated against all previously registered information on
the same person. In some cases, the NIPH contact the
clinician to clarify information. Data collected includes
mode of transmission, place of infection and clinical
information. Sexual orientation is not specifically asked
for on the notification form, but some clinicians report
it. The national guidelines for screening of hepatitis B,
recommend screening of immigrant populations from
high endemic countries, particularly asylum seekers,
including children adopted from abroad.
Case definitions
Cases are classified as acute hepatitis B in these two
situations:
1: Cases with a laboratory-positive test result (positive
HBsAg test result combined with a positive test result
from at least one of the following microbiological tests:
HBeAg, anti-HBc (IgG or IgM) antibody, HBsAg neutra-
lisation test, or detection of HBV nucleic acid), and one
of the following: 1) a clinically compatible case with an
epidemiological link (known exposure to HBV) or 2) an
acute hepatitis case without a known chronic hepatitis B
virus infection or 3) another known reason for acute
hepatitis.
2: Cases with anti-HBc seroconversion during the last
12 months combined with a positive test result in at
least one of their most recent microbiological tests:
HBsAg, HBV nucleic acid, or anti-HBs in the absence of
vaccination against hepatitis B or treatment with specific
immunoglobulin.
Cases are classified as chronic hepatitis B in this situa-
tion: cases who do not fulfil criteria for acute hepatitis B
but who have a positive test result for HBsAg and anti-
HBc antibody in the first available testing.
Population
We used population and migration data from the Nor-
wegian Statistics Bureau (SSB). The total population has
increased from 4,273,634 in 1992 to 4,799,252 in 2009.
For the analysis immigrants were considered as those
born abroad and those born in Norway with at least one
parent born abroad, asylum seekers and those with
family reunification and other immigrants not specified
above.
The estimated number of intravenous drug users
(IDUs) (using the Mortality Multiplier method) was
o b t a i n e df r o mt h eN o r w e g i a nI nstitute for Alcohol and
Drug Research (SIRUS), and available for the years
2002-2007.
Analysis by place of birth was performed for chronic
hepatitis B in the period from 2003 to 2009 as this data
is more accurate. Since 2003 place of birth is included
in the MSIS database after linkage to the National Popu-
lation Registry.
Results
Acute hepatitis B
Before the period of our study and since the establish-
ment of hepatitis B surveillance in Norway in 1975, a
steady decrease in the incidence of acute hepatitis B was
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selective vaccination strategy in 1984. During the study
period in the late 1990s, a high incidence was again
observed; this was due to an outbreak of acute hepatitis
B and hepatitis A among IDUs [10]. Since 2000, there
has been a decrease in the annual incidence from 5.9 to
1.2/100,000 in 2009 (Figure 1). Between 1992 and 2009
3,053 cases of acute hepatitis B were registered in the
national surveillance system.
Acute hepatitis B was most common in men aged 20-
40 years. Young people aged 20-29 were affected over 6
times more than those aged 50-59 (IRR = 6.6 [3.3-
13.3]). Males were 2 times more likely to acquire the
disease (IRR = 2.4 [1.7-3.3]) than females. People in the
age group 16-19 years were 3 times more likely to
acquire the disease as compared to those aged 50-59
years (Figure 2). Ninety percent of those who acquired
acute hepatitis B were Norwegian and the annual inci-
dence varied from 0.5 in 1992 up to 10.9/100,000 in
1999 and then back down to 1.2/100,000 population in
2009. As for immigrants, the incidence varied from 3.8/
100,000 (1992) to 0.2/100,000 (2009) (IRR = 1.7 [0.8-
3.5]). Most of the cases had acquired the disease in Nor-
way (86%).
The main exposure for acute hepatitis B was the use
of intravenous drugs (n = 1,963, 64%) followed by sexual
activity (n = 718, 24%) of whom the majority (60%) did
not specify sexual orientation, 29% reported heterosex-
ual, and 11% homosexual activity. Exposure to infected
blood (needle stick, transfusion/transplantation, nosoco-
mial infection) accounted for less than 1% of cases
(Table 1).
Among those who reportedly acquired the disease
through sexual activity 70% acquired it in Norway and
29% abroad. Among those infected abroad 48% were
infected in Asia and 41% in European countries. Among
those who reported being infected through heterosexual
activity abroad 52% acquired it in Asia and 35% in Eur-
ope. For those reporting homosexual transmission the
equivalent values were 18% and 70%, respectively. For
unspecified sexual activity abroad 50% acquired it in
Asia and 41% in Europe.
The yearly number of cases of acute hepatitis B has
decreased from 468 in 1998 to 57 in 2009. In 2009
intravenous drug use as the likely transmission route
accounted for 40% of all acute hepatitis B cases and sex-
ual transmission for 51%, during late 1990s this propor-
tion was 82% and 14%, respectively (Figure 3). The
pattern of acute hepatitis B among IDUs changed during
the study period. The annual incidence ranged from 44/
Figure 1 Annual incidence of acute hepatitis B in Norway,
1992-2009. Data from 1977 added for completeness of the figure;
data for other Nordic countries included for comparison (http://data.
euro.who.int/cisid; http://www.epinorth.org).
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Figure 2 Mean annual incidence of acute hepatitis B by age
and sex, Norway, 1992-2009. Blue bars represent number of
males with acute hepatitis B per 100,000 population; purple bars
represent females with acute hepatitis B per 100,000 population.
Table 1 Registered routes of transmission of acute and
chronic hepatitis B, Norway 1992-2009
Acute hepatitis
B
Chronic hepatitis
B
Route of
transmission
Total reports % Total reports %
IDU 1963 64.3 415 4.2
Sexual activity: 718 23.5 408 4.2
heterosexual 207 28.8 8 0.1
homosexual 79 11.0 10 0.1
Sexual, unspecified 432 60.2 390 4.0
Mother-to-child 7 0.2 471 4.8
Nosocomial 7 0.2 20 0.2
Blood/transplantation 4 0.1 81 0.8
Needle stick 30 1.0 19 0.2
Other 21 0.7 174 1.8
Unknown 303 9.9 8212 83.8
Total: 3053 100 9800 100
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Page 3 of 7100,000 users in early 1990s to more than 3,500/100,000
users during an outbreak in 1999. This decreased to
approximately 1000/100,000 users being infected per
year in the period between 2000 and 2009. The majority
were males (74%).
Acute infection is more often diagnosed in urban
areas and more in the South. The highest proportion of
intravenous drug users among acute cases was observed
in Oslo (13%), Rogaland (11%) and Hordaland (10%)
counties.
Chronic hepatitis B
From 1992 to 2009, 9,800 newly diagnosed cases of
chronic hepatitis B have been registered. During the
1990s approximately 8/100,000 population of newly
diagnosed chronic hepatitis B were registered annually.
We observed three peaks in 1999, 2003 and 2009 (Fig-
ure 4).
Between 2003 and 2009, the reporting of country of
birth for chronic infection improved from 16% (2003) to
85% (2009). Of those with known country of birth (n =
3,232), 78% were born in African (36%) and Asian (42%)
countries. Of the African countries 58% were from East-
ern Africa and 24% - Western Africa; from Asia there
were 52% born in South-east Asia and 17% in Southern
Asia. Altogether 12% of infected persons were born in
Europe. Of those, 27% were born in Eastern Europe. 9%
of all chronic hepatitis B cases were born in Norway (n
= 284).
Immigrants were more than 90 times more likely to
be newly diagnosed with chronic hepatitis B than Nor-
wegians (NRR = 93 [71.9-120.6]). This was particularly
evident for immigrants born abroad (NRR = 61 [46.7-
80.4]). Chronic HBV infection among those born in
Norway with at least one parent born abroad was less
common (NR = 1/100,000 population; NRR = 0 [0-2.3]).
Chronic HBV infection was slightly more common
among males than females (NRR = 1.5 [1.3-1.8]). It was
also more common among those aged 20-40 years com-
paring to those aged 50-59 (20-29: NRR = 5.2 [3.5-7.9],
30-39: NRR = 4.2 [2.8-6.3]). An increase of the notifica-
tion rate was observed in the age group 16-19 15.3/
100,000 (Figure 5).
The exposure is not known in the majority (83%) of
cases. Of the known factors, mother-to-child transmis-
sion was observed in almost 5% of the newly diagnosed
cases, followed by injectingd r u gu s e( 4 % )a n ds e x u a l
activity (4%) (Table 1).
Discussion
This study describes the epidemiology of acute hepatitis
B and chronic HBV infection in Norway between 1992-
2009. In accordance with the results from other Eur-
opean countries, acute hepatitis B most commonly
occurs amongst injecting drug users [5,11]. Chronic
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Figure 3 Proportion of registered routes of transmission for
acute hepatitis B, Norway, 1992-2009 (n = 3053). Proportion of
routes of transmission for acute hepatitis B are presented with three
colours: sexual route of transmission is presented with a dark blue
line; a pink line represents injecting drug use and unknown and/or
other routes of transmission are presented in orange colour.
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Figure 4 Notification rate of chronic hepatitis B, Norway 1992-
2009.
0
5
10
15
20
25
30
<1 1-15 16-19 20-29 30-39 40-49 50-59 60-69 70-79 80-89 >=90 Total 
Age group (years)
N
o
t
i
f
i
c
a
t
i
o
n
s
 
p
e
r
 
1
0
0
,
0
0
0
 
p
o
p
u
l
a
t
i
o
n
Male
Female
Figure 5 Mean annual notification rate of chronic hepatitis B
by age and sex, Norway, 1992-2009. Blue bars represent number
of notifications of chronic hepatitis B among males per 100,000
population; purple bars represent number of notifications of chronic
hepatitis B among females per 100,000 population.
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Page 4 of 7infection is mostly affecting immigrants from high ende-
mic parts of the world [6,12].
Nearly all the diagnosed cases of HBV infection are
reported to the national surveillance system as labora-
tories mandatorily report all tests that have positive
HBV markers. Clinicians also report a large proportion
(80%) of the laboratory reported cases of acute hepatitis
B. Therefore, there is a good overview on the disease in
Norway. Nevertheless additionally to existing under-
reporting only 30% of acute HBV cases would develop
jaundice, which is the main reason to seek medical care
among HBV patients [13].
There is no data in the surveillance system as to
whether the person has been exposed to more than one
risk factor (i.e. intravenous drug use and sex); although
clinicians can report both. Nevertheless it is difficult to
recognize which exposure caused the infection first.
There is no data on HIV co-infection or other sexually
transmitted infections.
Data for chronic HBV infection is not as accurate as
for acute hepatitis B: exposure is unknown in 83% of
notifications. It is difficult for clinicians to obtain infor-
mation from immigrant populations from highly ende-
mic countries, reflecting low reporting coverage.
The hepatitis B incidence in Norway is in the same
range as other Nordic countries (Figure 1). Although, it
is difficult to compare data from these countries as
some surveillance systems do not distinguish between
acute and chronic infection [4].
The increase in the late 1990s was due to a nation-
wide outbreak of hepatitis A and hepatitis B among
IDUs [10,14]. Similar outbreaks were observed in Fin-
land, Sweden and the Baltic countries, mainly among
groups of non-immune IDUs [14,15]. These outbreaks
coincided with increased number of IDUs and reduced
drug prices [10,14,16].
While the estimated number of IDUs was stable
between 2004 and 2008 [17], the number of IDUs with
acute hepatitis B has decreased. According to the Nor-
wegian Institute for Alcohol and Drug Research it
might be a result of decrease in heroin users in the
country which is probably related to a substantial
increase in the availability of substitution treatment dur-
ing the period [17]. Stabilization in the number of IDUs
has also been observed in other European countries
[18]. The decreasing incidence might also be due to
vaccination of IDUs and their close contacts. Screening
of a group of IDUs in Oslo (2009) indicates 35% vacci-
nation coverage (unpublished data). The number of car-
riers (anti-HBc positive) among IDUs in Oslo has
decreased from 50% in 2002 to 45% in 2007 [19]. In
addition, following the large outbreak in late 1990s, the
number of susceptible individuals has probably been
considerably reduced.
Even though Norway is one of the countries with well
established preventive measures for marginalised popu-
lations like IDUs, sexual activity with this risk group
contributes to further spread of the infection. The pro-
portion of cases infected through sexual activity has
slightly increased in early 2000s following the outbreak
among IDUs and has increased in 2009 (Figure 3). A
larger proportion of males among those with acute
hepatitis B is explained by the preponderance of males
amongst IDUs. Surveillance data suggests sexual activity
to be the second most important exposure. This is well
recognized in other low prevalence countries [20,21].
For more than half of the cases of acute hepatitis B sex-
ual orientation is not specified and this group is mostly
represented by males (62%), partly covering all types of
sexual orientation. The lack of information about sexual
orientation is due to the ethical considerations of perso-
nal identification of the patient, therefore this data is
not included in the notification form, preventing clini-
cians of asking for this kind of information.
Homosexual orientation was mentioned by 11% of
those with known sexual orientation, all males. MSM
are a well recognized risk group for hepatitis B and
other STIs [11,22]. Vaccination is in place for this group
in Norway as in other countries [4]. Although, vaccina-
tion coverage is not monitored, a web-based survey
among MSM in Norway in 2007 [23] revealed a cover-
age of 47% among respondents (unpublished data). This
is in line with a study from USA [24]. The injecting
drug use among Norwegian MSM is unknown, however
it is interesting to note that injecting drug use was
uncommon among MSM recruited in the Amsterdam
Cohort Studies [22].
Age distribution of the cases of acute hepatitis B with
high incidence starting in age group 16-19 years reflects
the onset of injecting drug use and sexual activity
[17,25].
Although the mode of transmission was unknown in
83% of the chronic hepatitis B cases, we assume that
almost all have been infected at birth or early in child-
hood [26].
The increase of newly diagnosed chronic hepatitis B in
the last years of the study period is closely related to the
increasing number of immigrants from countries with a
higher prevalence of hepatitis B. The immigrant popula-
tion represents 10% of the Norwegian population, with a
twofold increase in residents of Asian, African, South
and Central American origins since the early 90’s, and a
six fold increase in residents of Eastern European origin
(SSB).
Immigrant populations from highly endemic countries
have an impact on overall prevalence [12]. However,
further infection from the immigrant population is quite
limited [12]. Additionally, a molecular study by Fisker et
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general population than IDUs [20].
Hepatitis B screening of immigrants is in place in
Norway. However, there is little data regarding the
uptake of testing and vaccination amongst these popula-
tions. Certain immigrant populations are both hard to
reach and to convince as to the merits of testing, this
may be due to cultural differences.
Countries with selective vaccination strategy have low
prevalence of the disease and behavioural risk groups
are the main source of the infection. Low vaccination
coverage among MSM and IDUs are in line with some
studies, therefore suggesting a reconsideration of a uni-
versal vaccination strategy [21,27,28].
Conclusions
We aimed to describe reported cases of acute and
chronic hepatitis B virus infection in Norway between
1992 and 2009 in order to assess the validity of current
risk groups and recommend preventive measures.
Norway currently has a low incidence of acute hepati-
tis B. Following an outbreak in the 1990s IDUs have
remained the largest risk group for acute infection. Vac-
cination, availability of needles and syringes and the
decreasing number of IDUs have probably contributed
to the decreasing number of cases in this group.
Chronic HBV infection is closely related to the
increase in the immigrant population from highly ende-
mic countries. Therefore, screening of these populations
and vaccination, if needed, is essential to prevent further
spread of infection.
Screening of pregnant women, particularly immigrants
from high and intermediate countries and contacts of
IDUs, is necessary. Furthermore, given the high cost and
logistical challenges of selective vaccination strategy,
universal vaccination should be considered. Also, we
recommend formal evaluation of the effectiveness of
screening and vaccinating immigrant populations and of
the hepatitis B surveillance system.
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